Skip to main content

Commercialization of catalytic enhancers targeting IDO1 for multiple sclerosis

Project description

A novel drug against multiple sclerosis

Multiple sclerosis (MS) is a chronic neurodegenerative disease characterised by debilitating relapses associated with loss of neurological function. MS affects millions of individuals worldwide, but existing treatment options are primarily palliative. The EU-funded ENHANCIDO project aims to evaluate novel small molecules potentiating the activity of the immunosuppressive enzyme IDO1 known to reduce MS severity in animal models. By evaluating the efficacy, pharmacokinetics and pharmacodynamics of these compounds, scientists hope to deliver an innovative first-in-class drug that will improve the lives of MS patients. More importantly, this drug has the potential to be used to treat other autoimmune diseases.

Host institution

UNIVERSITA DEGLI STUDI DI PERUGIA
Net EU contribution
€ 150 000,00
Address
Piazza Dell Universita 1
06123 Perugia
Italy

See on map

Region
Centro (IT) Umbria Perugia
Activity type
Higher or Secondary Education Establishments
Other funding
No data

Beneficiaries (1)

UNIVERSITA DEGLI STUDI DI PERUGIA
Italy
Net EU contribution
€ 150 000,00
Address
Piazza Dell Universita 1
06123 Perugia

See on map

Region
Centro (IT) Umbria Perugia
Activity type
Higher or Secondary Education Establishments
Other funding
No data